Tesofensine for Stubborn Weight Management

Candidate profile

Adults with obesity (BMI ≥30 or ≥27 with comorbidities) who:

• Have not achieved adequate weight loss with GLP-1 agonists (semaglutide/tirzepatide) — either insufficient response (<5% weight loss at adequate doses) or intolerance (severe GI side effects)
• Have significant food reward/craving component to their eating behavior (dopaminergic component)
• Have normal baseline cardiovascular health (no uncontrolled hypertension, arrhythmias, or coronary artery disease)
• Understand the investigational nature of tesofensine (not FDA-approved)

Not appropriate for:

• Individuals with uncontrolled hypertension, tachycardia, or cardiac arrhythmias
• History of stimulant abuse or dependence
• Concurrent use of MAO inhibitors, other stimulants, or serotonergic medications (serotonin syndrome risk)
• Individuals who could achieve adequate results with FDA-approved options

Approach

Tesofensine is a triple monoamine reuptake inhibitor (serotonin + norepinephrine + dopamine) that addresses obesity through:

1. Appetite suppression: Serotonin and norepinephrine in hypothalamic feeding circuits
2. Increased energy expenditure: Norepinephrine-driven thermogenesis
3. Reduced food reward/craving: Dopamine in mesolimbic reward pathways

This triple mechanism distinguishes tesofensine from single-pathway agents and addresses the hedonic eating component that GLP-1 agonists may not fully control.

Protocol

Starting dose and titration

• Week 1–2: 0.25 mg daily (assess cardiovascular tolerance)
• Week 3–4: 0.5 mg daily (target dose for most individuals)
• Maximum: 0.5 mg (the 1.0 mg dose from Phase II trials showed unacceptable cardiovascular effects)

Timing: Morning administration (avoid evening dosing due to potential insomnia)

With food: Can be taken with or without food (not food-dependent like GLP-1s)

Duration: Continuous use under ongoing medical supervision

Cardiovascular monitoring protocol

This is non-negotiable due to tesofensine's sympathomimetic effects:

Parameter	Frequency	Action Threshold
Resting heart rate	Weekly × 4, then monthly	>100 bpm sustained or >15 bpm increase
Blood pressure	Weekly × 4, then monthly	>140/90 or >10 mmHg increase from baseline
ECG	Baseline + week 4	New arrhythmia or QTc prolongation
Symptoms	Continuous self-monitoring	Palpitations, chest pain, dyspnea

If thresholds exceeded: Reduce to 0.25 mg or discontinue. Do not exceed 0.5 mg in attempt to push through cardiovascular effects.

Adjunctive measures (required)

Tesofensine is not a standalone solution:

• Caloric deficit (500–750 kcal below maintenance)
• Resistance training (2–3× weekly) to preserve lean mass
• Protein intake ≥1.6 g/kg bodyweight
• Sleep optimization (tesofensine may affect sleep — manage proactively)

What to monitor

Primary outcomes

• Body weight: Weekly weigh-in (first morning, fasted)
• Waist circumference: Monthly (central adiposity is the metabolic-risk-relevant measure)
• Body composition: DEXA scan at baseline and 12 weeks (if available)

Metabolic markers (monthly)

• Fasting glucose and HbA1c
• Lipid panel (total cholesterol, LDL, HDL, triglycerides)
• Liver enzymes (ALT, AST)

Safety markers

• Blood pressure and heart rate (as above)
• Sleep quality assessment (insomnia is common with monoamine reuptake inhibitors)
• Mood assessment (dopamine/serotonin modulation can affect mood — positively or negatively)
• Dry mouth severity (most common side effect)

Timeline and expectations

Phase II data as reference

The TIPO-1 trial provides the best expectation calibrator:

• Placebo: 2.2% weight loss over 24 weeks
• 0.25 mg: 6.5% weight loss
• 0.5 mg: 12.8% weight loss
• 1.0 mg: 14.1% weight loss (unacceptable CV effects)

Realistic individual expectations

Weeks 1–4:

• Noticeable appetite suppression (especially reduced snacking and food preoccupation)
• 2–4% weight loss (partially water/glycogen)
• Possible side effects: dry mouth, constipation, mild insomnia
• Cardiovascular assessment period (confirm tolerability)

Weeks 4–12:

• Steady weight loss of 1–2% per month
• Reduced food reward responses (less hedonic eating)
• Improved energy (norepinephrine effect)
• Side effects typically stabilize

Weeks 12–24:

• Cumulative 8–13% weight loss in responders
• Metabolic markers improving (glucose, lipids)
• Weight loss rate may plateau (metabolic adaptation)

Non-response

If <3% weight loss after 8 weeks at 0.5 mg with adherence to caloric deficit:

• Confirm adherence to diet (caloric intake tracking)
• Consider that tesofensine mechanism may not address this individual's obesity phenotype
• Re-evaluate alternative approaches

Comparison with GLP-1 agonists

Parameter	Tesofensine 0.5 mg	Semaglutide 2.4 mg	Tirzepatide 15 mg
Weight loss (24 wk)	~13%	~10% (at 24 wk; ~15% at 68 wk)	~15% (at 24 wk)
Mechanism	Triple reuptake inhibitor	GLP-1 receptor agonist	GLP-1/GIP dual agonist
Route	Oral (daily)	SubQ (weekly)	SubQ (weekly)
Main side effects	CV (HR, BP), dry mouth, insomnia	GI (nausea, vomiting, diarrhea)	GI (nausea, vomiting)
FDA approved	No	Yes (Wegovy)	Yes (Zepbound)
Muscle loss concern	Less (dopamine may be muscle-sparing)	Yes (30–40% lean mass loss)	Yes

Key differentiators for tesofensine

1. Oral route: No injections (compliance advantage for needle-averse)
2. Dopamine component: Addresses food reward/craving that GLP-1s may miss
3. Less GI distress: Mechanism doesn't directly slow gastric emptying
4. Potential muscle-sparing: Catecholamine-driven metabolism may preferentially target fat

Key advantages of GLP-1s over tesofensine

1. FDA-approved: Regulatory validation, insurance coverage potential
2. Cardiovascular safety data: MACE reduction demonstrated (SELECT trial)
3. Multi-organ benefits: Hepatic, cardiovascular, renal protective effects
4. Long-term data: Multi-year outcome studies exist
5. No cardiac stimulation: Actually cardioprotective

Safety emphasis

Tesofensine's mechanism is fundamentally stimulatory (increasing catecholamines). This carries inherent cardiovascular risk that GLP-1 agonists do not share. The decision to use tesofensine should be made with full awareness of:

• No long-term (>24 week) safety data in obesity populations
• No cardiovascular outcome trials
• Mechanism similar to drugs withdrawn for CV safety (sibutramine)
• Requires ongoing cardiovascular monitoring

This use case represents a risk-aware choice by informed individuals who cannot tolerate or respond to safer first-line options — not a first-line recommendation.